ITPA (inosine triphosphate pyrophosphatase): From surveillance of nucleotide pools to human disease and pharmacogenetics

Mutation Research - Reviews in Mutation Research

Volumn 753, Issue 2, 2013, Pages 131-146

  Simone, Peter D ^a   Pavlov, Youri I ^a,b   Borgstahl, Gloria E O ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b ST PETERSBURG STATE UNIVERSITY   (Russian Federation)

Author keywords

Base analogs; Dominant negative; DSB; HAM1; HAP; HGPRT; ITP; ITPA; ITPA gene polymorphism; MEF; Mercaptopurines; Nucleotide pool; NUDT16; Pharmacogenetics; Protein stability; SSB; TPMT; XTP

Indexed keywords

3 METHYLADENINE; ACID ANHYDRIDE HYDROLASE; ADENYLOSUCCINATE SYNTHASE; AZATHIOPRINE; CYTOSINE; DNA POLYMERASE; ENDONUCLEASE; GUANINE; HYPOXANTHINE; INORGANIC PYROPHOSPHATASE; INOSINATE DEHYDROGENASE; INOSINE; INOSINE TRIPHOSPHATE; INOSINE TRIPHOSPHATE PYROPHOSPHATASE; MERCAPTOPURINE; METHOTREXATE; NUCLEOTIDE; PHOSPHORIBOSYLTRANSFERASE; PROLINE; RIBAVIRIN; RNA; RNA POLYMERASE II; THREONINE; UNCLASSIFIED DRUG; XANTHOSINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLELE; AMINO ACID SUBSTITUTION; AUTOIMMUNE DISEASE; BONE MARROW TOXICITY; CHROMOSOMAL INSTABILITY; DNA DAMAGE; DNA POLYMORPHISM; DNA REPAIR; DNA SYNTHESIS; DRUG EFFICACY; DRUG ERUPTION; DRUG METABOLISM; DRUG SAFETY; ENTERITIS; ENZYME ANALYSIS; ENZYME DEFICIENCY; ENZYME STRUCTURE; ERYTHROCYTE; ESCHERICHIA COLI; EXON; GASTROINTESTINAL TOXICITY; GENE EXPRESSION; GENE MUTATION; GENETIC CODE; GENETIC POLYMORPHISM; HEMOLYSIS; HEMOLYTIC ANEMIA; HEPATITIS C; HUMAN; HYDROPHOBICITY; INOSINE TRIPHOSPHATE PYROPHOSPHATASE DEFICIENCY; LESCH NYHAN SYNDROME; LEUKEMIA; LEUKOPENIA; LIVER TOXICITY; LOW DRUG DOSE; MENTAL DEFICIENCY; NODULAR HYPERPLASIA; NONHUMAN; PANCREATITIS; PARANOIA; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN FUNCTION; RASH; REVIEW; RHEUMATOID ARTHRITIS; RNA SYNTHESIS; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; UNSPECIFIED SIDE EFFECT;

MUS;

EID: 84887021703     PISSN: 13835742     EISSN: 13882139     Source Type: Journal    
DOI: 10.1016/j.mrrev.2013.08.001     Document Type: Review

References (136)

1. Lin S., McLennan A.G., Ying K., Wang Z., Gu S., Jin H., Wu C., Liu W., Yuan Y., Tang R., Xie Y., Mao Y. Cloning, expression, and characterization of a human inosine triphosphate pyrophosphatase encoded by the ITPA gene. J. Biol. Chem. 2001, 276:18695-18701.
2. Clyman J., Cunningham R.P. Escherichia coli K-12 mutants in which viability is dependent on recA function. J. Bacteriol. 1987, 169:4203-4210.
3. Pavlov Y.I. Saccharomyces cerevisiae mutants highly sensitive to the mutagenic action of 6-N-hydroxylaminopurine. Sov. Genet. 1986, 22:1099-1107.
4. Behmanesh M., Sakumi K., Abolhassani N., Toyokuni S., Oka S., Ohnishi Y.N., Tsuchimoto D., Nakabeppu Y. ITPase-deficient mice show growth retardation and die before weaning. Cell Death Differ. 2009, 16:1315-1322.
5. Marinaki A.M., Ansari A., Duley J.A., Arenas M., Sumi S., Lewis C.M., Shobowale-Bakre e.-M., Escuredo E., Fairbanks L.D., Sanderson J.D. Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase). Pharmacogenetics 2004, 14:181-187.
6. Fellay J., Thompson A.J., Ge D., Gumbs C.E., Urban T.J., Shianna K.V., Little L.D., Qiu P., Bertelsen A.H., Watson M., Warner A., Muir A.J., Brass C., Albrecht J., Sulkowski M., McHutchison J.G., Goldstein D.B. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature 2010, 464:405-408.
7. Sumi S., Marinaki A.M., Arenas M., Fairbanks L., Shobowale-Bakre M., Rees D.C., Thein S.L., Ansari A., Sanderson J., De Abreu R.A., Simmonds H.A., Duley J.A. Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency. Hum. Genet. 2002, 111:360-367.
8. Cao H., Hegele R.A. DNA polymorphisms in ITPA including basis of inosine triphosphatase deficiency. J. Hum. Genet. 2002, 47:620-622.
9. Waisertreiger I.S., Menezes M.R., Randazzo J., Pavlov Y.I. Elevated Levels of DNA Strand Breaks Induced by a Base Analog in the Human Cell Line with the P32T ITPA Variant. J. Nucleic Acids 2010.
10. Simone P.D., Struble L.R., Kellezi A., Brown C.A., Grabow C.E., Khutsishvili I., Marky L.A., Pavlov Y.I., Borgstahl G.E. The human ITPA polymorphic variant P32T is destabilized by the unpacking of the hydrophobic core. J. Struct. Biol. 2013, 23:78-86.
11. Liakopoulou A., Alivisatos S.G. Distribution of Nucleoside Triphosphatases in Human Erythrocytes. Biochim. Biophys. Acta 1964, 89:158-161.
12. Vanderheiden B.S. Human erythrocyte ITPase: an ITP pyrophosphohydrolase. Biochim. Biophys. Acta 1970, 215:555-558.
13. Vanderheiden B.S. Purification and properties of human erythrocyte inosine triphosphate pyrophosphohydrolase. J. Cell. Physiol. 1979, 98:41-47.
14. Holmes S.L., Turner B.M., Hirschhorn K. Human inosine triphosphatase: catalytic properties and population studies. Clin. Chim. Acta 1979, 97:143-153.
15. Burgis N.E., Cunningham R.P. Substrate specificity of RdgB protein, a deoxyribonucleoside triphosphate pyrophosphohydrolase. J. Biol. Chem. 2007, 282:3531-3538.
16. Porta J., Kolar C., Kozmin S.G., Pavlov Y.I., Borgstahl G.E. Structure of the orthorhombic form of human inosine triphosphate pyrophosphatase. Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun. 2006, 62:1076-1081.
17. Stenmark P., Kursula P., Flodin S., Graslund S., Landry R., Nordlund P., Schuler H. Crystal structure of human inosine triphosphatase. Substrate binding and implication of the inosine triphosphatase deficiency mutation P32T. J. Biol. Chem. 2007, 282:3182-3187.
18. Stepchenkova E.I., Tarakhovskaya E.R., Spitler K., Frahm C., Menezes M.R., Simone P.D., Kolar C., Marky L.A., Borgstahl G.E., Pavlov Y.I. Functional study of the P32T ITPA variant associated with drug sensitivity in humans. J. Mol. Biol. 2009, 392:602-613.
19. Herting G., Barber K., Zappala M.R., Cunningham R.P., Burgis N.E. Quantitative in vitro and in vivo characterization of the human P32T mutant ITPase. Biochim. Biophys. Acta 2010, 1802:269-274.
20. Vanderheiden B.S. Micro assay of ITP pyrophosphohydrolase by liquid scintillation. Anal. Biochem. 1972, 49:459-466.
21. Herz F. Effect of heat and nucleotides on human erythrocyte inorganic pyrophosphatase. Proc. Soc. Exp. Biol. Med. 1967, 125:68-70.
22. Andersen O. Chelation of cadmium. Environ. Health Perspect. 1984, 54:249-266.
23. Wieland M., Levin M.K., Hingorani K.S., Biro F.N., Hingorani M.M. Mechanism of cadmium-mediated inhibition of Msh2-Msh6 function in DNA mismatch repair. Biochemistry 2009, 48:9492-9502.
24. Miessler G.L., Tarr D.A. Inorganic Chemistry 2004, Pearson Prentice Hall, Upper Saddle River, New Jersey. 3rd ed.
25. Lokanath N.K., Pampa K.J., Takio K., Kunishima N. Structures of dimeric nonstandard nucleotide triphosphate pyrophosphatase from Pyrococcus horikoshii OT3: functional significance of interprotomer conformational changes. J. Mol. Biol. 2008, 375:1013-1025.
26. Hwang K.Y., Chung J.H., Kim S.H., Han Y.S., Cho Y. Structure-based identification of a novel NTPase from Methanococcus jannaschii. Nat. Struct. Biol. 1999, 6:691-696.
27. Savchenko A., Proudfoot M., Skarina T., Singer A., Litvinova O., Sanishvili R., Brown G., Chirgadze N., Yakunin A.F. Molecular basis of the antimutagenic activity of the house-cleaning inosine triphosphate pyrophosphatase RdgB from Escherichia coli. J. Mol. Biol. 2007, 374:1091-1103.
28. Voet D., Voet J.G., Pratt C.W. Fundamentals of Biochemistry 2002, John Wiley & Sons, Inc, New York, New York. Upgrade ed.
29. 14C. Nature 1967, 216:1036-1037.
30. Zachara B., Lewandowski J. Isolation and identification of inosine triphosphate from human erythrocytes. Biochim. Biophys. Acta 1974, 353:253-259.
31. Fraser J.H., Meyers H., Henderson J.F., Brox L.W., McCoy E.E. Individual variation in inosine triphosphate accumulation in human erythrocytes. Clin. Biochem. 1975, 8:353-364.
32. Soder C., Henderson J.F., Zombor G., McCoy E.E., Verhoef V., Morris A.J. Relationships between nucleoside triphosphate pyrophosphohydrolase activity and inosine triphosphate accumulation in human erythrocytes. Can. J. Biochem. 1976, 54:843-847.
33. Henderson J.F., Zombor G., Fraser J.H., McCoy E.E., Verhoef V., Morris A.J. Factors affecting inosinate synthesis and inosine triphosphate accumulation in human erythrocytes. Can. J. Biochem. 1977, 55:359-364.
34. Vanderheiden B.S. Inosine di- and triphosphate synthesis in erythrocytes and cell extracts. J. Cell. Physiol. 1979, 99:287-301.
35. Agarwal R.P., Scholar E.M., Agarwal K.C., Parks R.E. Identification and isolation on a large scale of guanylate kinase from human erythrocytes. Effects of monophosphate nucleotides of purine analogs. Biochem. Pharmacol. 1971, 20:1341-1354.
36. Ren H., Wang L., Bennett M., Liang Y., Zheng X., Lu F., Li L., Nan J., Luo M., Eriksson S., Zhang C., Su X.D. The crystal structure of human adenylate kinase 6: An adenylate kinase localized to the cell nucleus. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:303-308.
37. Myrnes B., Guddal P.H., Krokan H. Metabolism of dITP in HeLa cell extracts, incorporation into DNA by isolated nuclei and release of hypoxanthine from DNA by a hypoxanthine-DNA glycosylase activity. Nucleic Acids Res. 1982, 10:3693-3701.
38. Shapiro R., Pohl S.H. The reaction of ribonucleosides with nitrous acid. Side products and kinetics. Biochemistry 1968, 7:448-455.
39. Dedon P.C., Barth M., Chen B., De Mott M., Dendroulakis V., Dong M., Kalinga S., Elmquist E., Margolin Y., Pang B., Zhou X. Diverse Mechanisms of Endogenous Nucleobase Deamination in DNA and RNA. Advances in Molecular Toxicology 2006, 25-63. Elsevier. C.F. James (Ed.).
40. Karran P., Lindahl T. Hypoxanthine in deoxyribonucleic acid: generation by heat-induced hydrolysis of adenine residues and release in free form by a deoxyribonucleic acid glycosylase from calf thymus. Biochemistry 1980, 19:6005-6011.
41. Martin F.H., Castro M.M., Aboul-ela F., Tinoco I. Base pairing involving deoxyinosine: implications for probe design. Nucleic Acids Res. 1985, 13:8927-8938.
42. Thomas M.J., Platas A.A., Hawley D.K. Transcriptional fidelity and proofreading by RNA polymerase II. Cell 1998, 93:627-637.
43. Dierick H., Stul M., De Kelver W., Marynen P., Cassiman J.J. Incorporation of dITP or 7-deaza dGTP during PCR improves sequencing of the product. Nucleic Acids Res. 1993, 21:4427-4428.
44. Bessman M.J., Lehman I.R., Adler J., Zimmerman S.B., Simms E.S., Kornberg A. Enzymatic synthesis of deoxyribonucleic acid. Iii. The incorporation of pyrimidine and purine analogues into deoxyribonucleic acid. Proc. Natl. Acad. Sci. U.S.A. 1958, 44:633-640.
45. Pang B., McFaline J.L., Burgis N.E., Dong M., Taghizadeh K., Sullivan M.R., Elmquist C.E., Cunningham R.P., Dedon P.C. Defects in purine nucleotide metabolism lead to substantial incorporation of xanthine and hypoxanthine into DNA and RNA. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:2319-2324.
46. Suzuki T., Yoshida M., Yamada M., Ide H., Kobayashi M., Kanaori K., Tajima K., Makino K. Misincorporation of 2'-deoxyoxanosine 5'-triphosphate by DNA polymerases and its implication for mutagenesis. Biochemistry 1998, 37:11592-11598.
47. Sakumi K., Abolhassani N., Behmanesh M., Iyama T., Tsuchimoto D., Nakabeppu Y. ITPA protein, an enzyme that eliminates deaminated purine nucleoside triphosphates in cells. Mutat. Res. 2010, 703:43-50.
48. Budke B., Kuzminov A. Hypoxanthine incorporation is nonmutagenic in Escherichia coli. J. Bacteriol. 2006, 188:6553-6560.
49. Burgis N.E., Brucker J.J., Cunningham R.P. Repair system for noncanonical purines in Escherichia coli. J. Bacteriol. 2003, 185:3101-3110.
50. Budke B., Kuzminov A. Production of clastogenic DNA precursors by the nucleotide metabolism in Escherichia coli. Mol. Microbiol. 2010, 75:230-245.
51. Kamiya H., Shimizu M., Suzuki M., Inoue H., Ohtsuka E. Mutation induced by deoxyxanthosine in Codon 12 of a Synthetic c-Ha-ras Gene. Nucleosides Nucleotides 1992, 11:247-260.
52. Kamiya H. Mutagenic potentials of damaged nucleic acids produced by reactive oxygen/nitrogen species: approaches using synthetic oligonucleotides and nucleotides: survey and summary. Nucleic Acids Res. 2003, 31:517-531.
53. Kamiya H., Miura H., Kato H., Nishimura S., Ohtsuka E. Induction of mutation of a synthetic c-Ha-ras gene containing hypoxanthine. Cancer Res. 1992, 52:1836-1839.
54. Nordmann P.L., Makris J.C., Reznikoff W.S. Inosine induced mutations. Mol. Gen. Genet. 1988, 214:62-67.
55. Caldecott K.W. Single-strand break repair and genetic disease. Nat. Rev. Genet. 2008, 9:619-631.
56. Kuzminov A. Single-strand interruptions in replicating chromosomes cause double-strand breaks. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:8241-8246.
57. Shrivastav M., De Haro L.P., Nickoloff J.A. Regulation of DNA double-strand break repair pathway choice. Cell Res. 2008, 18:134-147.
58. He B., Qing H., Kow Y.W. Deoxyxanthosine in DNA is repaired by Escherichia coli endonuclease V. Mutat. Res. 2000, 459:109-114.
59. Bradshaw J.S., Kuzminov A. RdgB acts to avoid chromosome fragmentation in Escherichia coli. Mol. Microbiol. 2003, 48:1711-1725.
60. Moe A., Ringvoll J., Nordstrand L.M., Eide L., Bjoras M., Seeberg E., Rognes T., Klungland A. Incision at hypoxanthine residues in DNA by a mammalian homologue of the Escherichia coli antimutator enzyme endonuclease V. Nucleic Acids Res. 2003, 31:3893-3900.
61. Mi R., Alford-Zappala M., Kow Y.W., Cunningham R.P., Cao W. Human endonuclease V as a repair enzyme for DNA deamination. Mutat Res. 2012, 735:12-18. Epub 2012 Jun 1. 10.1016/j.mrfmmm.2012.05.003.
62. Cao W., Endonuclease V: an unusual enzyme for repair of DNA deamination. Cell Mol. Life Sci. 2012, 20:20.
63. Rosnes I., Rowe A.D., Vik E.S., Forstrom R.J., Alseth I., Bjoras M., Dalhus B. Structural basis of DNA loop recognition by endonuclease V. Structure 2013, 21:257-265. http://dx.doi.org/10.1016/j.str.2012.12.007. Epub 2013 Jan 11.
64. Karran P., Lindahl T. Enzymatic excision of free hypoxanthine from polydeoxynucleotides and DNA containing deoxyinosine monophosphate residues. J. Biol. Chem. 1978, 253:5877-5879.
65. Lee H.W., Dominy B.N., Cao W. New family of deamination repair enzymes in uracil-DNA glycosylase superfamily. J. Biol. Chem. 2011, 286:31282-31287.
66. Saparbaev M., Mani J.C., Laval J. Interactions of the human, rat, Saccharomyces cerevisiae and Escherichia coli 3-methyladenine-DNA glycosylases with DNA containing dIMP residues. Nucleic Acids Res. 2000, 28:1332-1339.
67. Daley J.M., Zakaria C., Ramotar D. The endonuclease IV family of apurinic/apyrimidinic endonucleases. Mutat. Res. 2010, 705:217-227.
68. Auclair C., Gouyette A., Levy A., Emerit I. Clastogenic inosine nucleotide as components of the chromosome breakage factor in scleroderma patients. Arch. Biochem. Biophys. 1990, 278:238-244.
69. Emerit I., Filipe P., Meunier P., Auclair C., Freitas J., Deroussent A., Gouyette A., Fernandes A. Clastogenic activity in the plasma of scleroderma patients: a biomarker of oxidative stress. Dermatology 1997, 194:140-146.
70. Vanderheiden B.S. Possible implication of an inosinetriphosphate metabolic error and glutamic acid decarboxylase in paranoid schizophrenia. Biochem. Med. 1979, 21:22-32.
71. Burton K., White H., Sleep J. Kinetics of muscle contraction and actomyosin NTP hydrolysis from rabbit using a series of metal-nucleotide substrates. J. Physiol. 2005, 563:689-711.
72. Osheroff N., Shelton E.R., Brutlag D.L. DNA topoisomerase II from Drosophila melanogaster. Relaxation of supercoiled DNA. J. Biol. Chem. 1983, 258:9536-9543.
73. 1-ATPase: does it exist?. J. Biol. Chem. 2001, 276:35422-35428.
74. i-proteins in HL-60 leukemia cell membranes. Biochem. Pharmacol. 1997, 54:551-562.
75. Noskov V.N., Staak K., Shcherbakova P.V., Kozmin S.G., Negishi K., Ono B.C., Hayatsu H., Pavlov Y.I. HAM1, the gene controlling 6-N-hydroxylaminopurine sensitivity and mutagenesis in the yeast Saccharomyces cerevisiae. Yeast 1996, 12:17-29.
76. Behmanesh M., Sakumi K., Tsuchimoto D., Torisu K., Ohnishi-Honda Y., Rancourt D.E., Nakabeppu Y. Characterization of the structure and expression of mouse Itpa gene and its related sequences in the mouse genome. DNA Res. 2005, 12:39-51.
77. Vanderheiden B.S. ITP pyrophosphohydrolase and IDP phosphohydrolase in rat tissue. J. Cell. Physiol. 1975, 86:167-175.
78. Chern C.J., MacDonald A.B., Morris A.J. Purification and properties of a nucleoside triphosphate pyrophosphohydrolase from red cells of the rabbit. J. Biol. Chem. 1969, 244:5489-5495.
79. Michel B. After 30 years of study, the bacterial SOS response still surprises us. PLoS Biol. 2005, 3:e255.
80. Kozmin S.G., Schaaper R.M., Shcherbakova P.V., Kulikov V.N., Noskov V.N., Guetsova M.L., Alenin V.V., Rogozin I.B., Makarova K.S., Pavlov Y.I. Multiple antimutagenesis mechanisms affect mutagenic activity and specificity of the base analog 6-N-hydroxylaminopurine in bacteria and yeast. Mutat. Res. 1998, 402:41-50.
81. Abolhassani N., Iyama T., Tsuchimoto D., Sakumi K., Ohno M., Behmanesh M., Nakabeppu Y. NUDT16 and ITPA play a dual protective role in maintaining chromosome stability and cell growth by eliminating dIDP/IDP and dITP/ITP from nucleotide pools in mammals. Nucleic Acids Res. 2010, 38:2891-2903.
82. Tsuchimoto D., Iyama T., Nonaka M., Abolhassani N., Ohta E., Sakumi K., Nakabeppu Y. A comprehensive screening system for damaged nucleotide-binding proteins. Mutat. Res. 2010, 703:37-42.
83. Vanderheiden B.S. Inosine triphosphate in human erythrocytes: A genetic trait. Proceedings of the 10th Congress of the International Society of Blood Transfusion, Stockholm, vol. 1964 1965, 540.
84. Vanderheiden B.S. Genetic studies of human erythrocyte inosine triphosphatase. Biochem. Genet. 1969, 3:289-297.
85. Verhoef V.L., Fuller S.A., Morris A.J. Individual variation of nucleoside triphosphate pyrophosphohydrolase activity in human erythrocytes, granulocytes, lymphocytes, and platelets. Biochem. Genet. 1980, 18:235-245.
86. Marsh S., King C.R., Ahluwalia R., McLeod H.L. Distribution of ITPA P32T alleles in multiple world populations. J. Hum. Genet. 2004, 49:579-581.
87. von Ahsen N., Oellerich M., Armstrong V.W. Characterization of the inosine triphosphatase (ITPA) gene: haplotype structure, haplotype-phenotype correlation and promoter function. Ther. Drug Monit. 2008, 30:16-22.
88. Heller T., Oellerich M., Armstrong V.W., von Ahsen N. Rapid detection of ITPA 94C>A and IVS2+21A>C gene mutations by real-time fluorescence PCR and in vitro demonstration of effect of ITPA IVS2+21A>C polymorphism on splicing efficiency. Clin. Chem. 2004, 50:2182-2184.
89. Arenas M., Duley J., Sumi S., Sanderson J., Marinaki A. The ITPA c.94C>A and g.IVS2+21A>C sequence variants contribute to missplicing of the ITPA gene. Biochim. Biophys. Acta 2007, 1772:96-102.
90. Shichijo S., Azuma K., Komatsu N., Kawamoto N., Takedatsu H., Shomura H., Sawamizu H., Maeda Y., Ito M., Itoh K. Identification of two novel tumor-associated antigens recognized by HLA-B46-restricted cytotoxic T lymphocytes. Int. J. Mol. Med. 2003, 12:895-902.
91. Poppe B., Vandesompele J., Schoch C., Lindvall C., Mrozek K., Bloomfield C.D., Beverloo H.B., Michaux L., Dastugue N., Herens C., Yigit N., De Paepe A., Hagemeijer A., Speleman F. Expression analyses identify MLL as a prominent target of 11q23 amplification and support an etiologic role for MLL gain of function in myeloid malignancies. Blood 2004, 103:229-235.
92. John T., Black M.A., Toro T.T., Leader D., Gedye C.A., Davis I.D., Guilford P.J., Cebon J.S. Predicting clinical outcome through molecular profiling in stage III melanoma. Clin. Cancer Res. 2008, 14:5173-5180.
93. Menezes M.R., Waisertreiger I.S., Lopez-Bertoni H., Luo X., Pavlov Y.I. Pivotal role of inosine triphosphate pyrophosphatase in maintaining genome stability and the prevention of apoptosis in human cells. PLoS ONE 2012, 7:e32313.
94. Vanderheiden B.S., Zarate-Moyano C. Erythrocyte ITP pyrophosphohydrolase deficiency in a psychiatric population. Biol. Psychiatry 1976, 11:755-765.
95. Vanderheiden B.S., Bora G. Erythrocyte ITP pyrophosphohydrolase in chronic paranoid and undifferentiated schizophrenics: a biological difference. Biochem. Med. 1980, 23:76-86.
96. Bakker J.A., Bierau J., Drent M. A role for ITPA variants in the clinical course of pulmonary Langerhans' cell histiocytosis?. Eur. Respir. J. 2010, 36:684-686.
97. Zamzami M.A., Duley J.A., Price G.R., Venter D.J., Yarham J.W., Taylor R.W., Catley L.P., Florin T.H., Marinaki A.M., Bowling F. Inosine Triphosphate Pyrophosphohydrolase (ITPA) polymorphic sequence variants in adult hematological malignancy patients and possible association with mitochondrial DNA defects. J. Hematol. Oncol. 2013, 6:24.
98. Marinaki A.M., Duley J.A., Arenas M., Ansari A., Sumi S., Lewis C.M., Shobowale-Bakre M., Fairbanks L.D., Sanderson J. Mutation in the ITPA gene predicts intolerance to azathioprine. Nucleosides Nucleotides Nucleic Acids 2004, 23:1393-1397.
99. Krynetski E.Y., Evans W.E. Pharmacogenetics of cancer therapy: getting personal. Am. J. Hum. Genet. 1998, 63:11-16.
100. Relling M.V., Hancock M.L., Rivera G.K., Sandlund J.T., Ribeiro R.C., Krynetski E.Y., Pui C.H., Evans W.E. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J. Natl. Cancer Inst. 1999, 91:2001-2008.
101. Gearry R.B., Roberts R.L., Barclay M.L., Kennedy M.A. Lack of association between the ITPA 94C>A polymorphism and adverse effects from azathioprine. Pharmacogenetics 2004, 14:779-781.
102. von Ahsen N., Armstrong V.W., Behrens C., von Tirpitz C., Stallmach A., Herfarth H., Stein J., Bias P., Adler G., Shipkova M., Oellerich M., Kruis W., Reinshagen M., Schutz E. Association of inosine triphosphatase 94C>A and thiopurine S-methyltransferase deficiency with adverse events and study drop-outs under azathioprine therapy in a prospective Crohn disease study. Clin. Chem. 2005, 51:2282-2288.
103. Zelinkova Z., Derijks L.J., Stokkers P.C., Vogels E.W., van Kampen A.H., Curvers W.L., Cohn D., van Deventer S.J., Hommes D.W. Inosine triphosphate pyrophosphatase and thiopurine S-methyltransferase genotypes relationship to azathioprine-induced myelosuppression. Clin. Gastroenterol. Hepatol. 2006, 4:44-49.
104. van Dieren J.M., van Vuuren A.J., Kusters J.G., Nieuwenhuis E.E., Kuipers E.J., van der Woude C.J. ITPA genotyping is not predictive for the development of side effects in AZA treated inflammatory bowel disease patients. Gut 2005, 54:1664.
105. Hindorf U., Lindqvist M., Peterson C., Soderkvist P., Strom M., Hjortswang H., Pousette A., Almer S. Pharmacogenetics during standardised initiation of thiopurine treatment in inflammatory bowel disease. Gut 2006, 55:1423-1431.
106. van Dieren J.M., Hansen B.E., Kuipers E.J., Nieuwenhuis E.E., Van der Woude C.J., Meta-analysis. Inosine triphosphate pyrophosphatase polymorphisms and thiopurine toxicity in the treatment of inflammatory bowel disease. Aliment. Pharmacol. Ther. 2007, 26:643-652.
107. Ansari A., Arenas M., Greenfield S.M., Morris D., Lindsay J., Gilshenan K., Smith M., Lewis C., Marinaki A., Duley J., Sanderson J. Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease. Aliment. Pharmacol. Ther. 2008, 28:973-983.
108. Stocco G., Cheok M.H., Crews K.R., Dervieux T., French D., Pei D., Yang W., Cheng C., Pui C.H., Relling M.V., Evans W.E. Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia. Clin. Pharmacol. Ther. 2009, 85:164-172.
109. Wan Rosalina W.R., Teh L.K., Mohamad N., Nasir A., Yusoff R., Baba A.A., Salleh M.Z. Polymorphism of ITPA 94C>A and risk of adverse effects among patients with acute lymphoblastic leukaemia treated with 6-mercaptopurine. J. Clin. Pharm. Ther. 2011, 37:237-241.
110. Adam de Beaumais T., Fakhoury M., Medard Y., Azougagh S., Zhang D., Yakouben K., Jacqz-Aigrain E. Determinants of mercaptopurine toxicity in paediatric acute lymphoblastic leukemia maintenance therapy. Br. J. Clin. Pharmacol. 2011, 71:575-584.
111. Shipkova M., Franz J., Abe M., Klett C., Wieland E., Andus T. Association between adverse effects under azathioprine therapy and inosine triphosphate pyrophosphatase activity in patients with chronic inflammatory bowel disease. Ther. Drug Monit. 2011, 33:321-328.
112. Buster E.H., van Vuuren H.J., Zondervan P.E., Metselaar H.J., Tilanus H.W., de Man R.A. Thiopurine-methyltransferase and inosine triphosphate pyrophosphatase polymorphism in a liver transplant recipient developing nodular regenerative hyperplasia on low-dose azathioprine. Eur. J. Gastroenterol. Hepatol. 2008, 20:68-72.
113. Okada Y., Nakamura K., Hiromura K., Nojima Y., Horiuchi R., Yamamoto K. Pro32Thr polymorphism of inosine triphosphate pyrophosphatase gene predicts efficacy of low-dose azathioprine for patients with systemic lupus erythematosus. Clin. Pharmacol. Ther. 2009, 85:527-530.
114. Yamamoto K., Okada Y., Nakamura K., Hiromura K., Nojima Y., Nakamura T. Inosine triphosphate pyrophosphatase 94C>A polymorphism: clinical implications for patients with systemic lupus erythematosus treated with azathioprine. Expert Opin. Drug Saf. 2010, 9:447-457.
115. Derijks L.J., Wong D.R. Pharmacogenetics of thiopurines in inflammatory bowel disease. Curr. Pharm. Des. 2010, 16:145-154.
116. Dewit O., Starkel P., Roblin X. Thiopurine metabolism monitoring: implications in inflammatory bowel diseases. Eur. J. Clin. Invest. 2010, 40:1037-1047.
117. Stocco G., Crews K.R., Evans W.E. Genetic polymorphism of inosine-triphosphate-pyrophosphatase influences mercaptopurine metabolism and toxicity during treatment of acute lymphoblastic leukemia individualized for thiopurine-S-methyl-transferase status. Expert Opin. Drug Saf. 2010, 9:23-37.
118. Bierau J., Lindhout M., Bakker J.A. Pharmacogenetic significance of inosine triphosphatase. Pharmacogenomics 2007, 8:1221-1228.
119. Bakker J.A., Lindhout M., Habets D.D., van den Wijngaard A., Paulussen A.D., Bierau J. The effect of ITPA polymorphisms on the enzyme kinetic properties of human erythrocyte inosine triphosphatase toward its substrates ITP and 6-Thio-ITP. Nucleosides Nucleotides Nucleic Acids 2011, 30:839-849.
120. Wessels J.A., Kooloos W.M., De Jonge R., De Vries-Bouwstra J.K., Allaart C.F., Linssen A., Collee G., De Sonnaville P., Lindemans J., Huizinga T.W., Guchelaar H.J. Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment in patients with recent-onset rheumatoid arthritis. Arthritis Rheum. 2006, 54:2830-2839.
121. Wessels J.A., van der Kooij S.M., le Cessie S., Kievit W., Barerra P., Allaart C.F., Huizinga T.W., Guchelaar H.J. A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. Arthritis Rheum. 2007, 56:1765-1775.
122. Dervieux T., Wessels J.A., van der Straaten T., Penrod N., Moore J.H., Guchelaar H.J., Kremer J.M. Gene-gene interactions in folate and adenosine biosynthesis pathways affect methotrexate efficacy and tolerability in rheumatoid arthritis. Pharmacogenet. Genomics 2009, 19:935-944.
123. Lee Y.C., Cui J., Costenbader K.H., Shadick N.A., Weinblatt M.E., Karlson E.W. Investigation of candidate polymorphisms and disease activity in rheumatoid arthritis patients on methotrexate. Rheumatology 2009, 48:613-617.
124. Kooloos W.M., Wessels J.A., van der Straaten T., Allaart C.F., Huizinga T.W., Guchelaar H.J. Functional polymorphisms and methotrexate treatment outcome in recent-onset rheumatoid arthritis. Pharmacogenomics 2010, 11:163-175.
125. Ochi H., Maekawa T., Abe H., Hayashida Y., Nakano R., Kubo M., Tsunoda T., Hayes C.N., Kumada H., Nakamura Y., Chayama K. ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy--a genome-wide study of Japanese HCV virus patients. Gastroenterology 2010, 139:1190-1197.
126. Thompson A.J., Fellay J., Patel K., Tillmann H.L., Naggie S., Ge D., Urban T.J., Shianna K.V., Muir A.J., Fried M.W., Afdhal N.H., Goldstein D.B., McHutchison J.G. Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction. Gastroenterology 2010, 139:1181-1189.
127. Sakamoto N., Tanaka Y., Nakagawa M., Yatsuhashi H., Nishiguchi S., Enomoto N., Azuma S., Nishimura-Sakurai Y., Kakinuma S., Nishida N., Tokunaga K., Honda M., Ito K., Mizokami M., Watanabe M. ITPA gene variant protects against anemia induced by pegylated interferon-alpha and ribavirin therapy for Japanese patients with chronic hepatitis C. Hepatol. Res. 2010, 40:1063-1071.
128. Suzuki F., Suzuki Y., Akuta N., Sezaki H., Hirakawa M., Kawamura Y., Hosaka T., Kobayashi M., Saito S., Arase Y., Ikeda K., Chayama K., Kamatani N., Nakamura Y., Miyakawa Y., Kumada H. Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir. Hepatology 2011, 53:415-421.
129. Chayama K., Hayes C.N., Abe H., Miki D., Ochi H., Karino Y., Toyota J., Nakamura Y., Kamatani N., Sezaki H., Kobayashi M., Akuta N., Suzuki F., Kumada H. IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C. J. Infect. Dis. 2011, 204:84-93.
130. Hitomi Y., Cirulli E.T., Fellay J., McHutchison J.G., Thompson A.J., Gumbs C.E., Shianna K.V., Urban T.J., Goldstein D.B. Inosine triphosphate protects against ribavirin-induced adenosine triphosphate loss by restoring adenylosuccinate synthase function. Gastroenterology 2011, 140:1314-1321.
131. Maeda T., Sumi S., Ueta A., Ohkubo Y., Ito T., Marinaki A.M., Kurono Y., Hasegawa S., Togari H. Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency in the Japanese population. Mol. Genet. Metab. 2005, 85:271-279.
132. Shipkova M., Lorenz K., Oellerich M., Wieland E., von Ahsen N. Measurement of erythrocyte inosine triphosphate pyrophosphohydrolase (ITPA) activity by HPLC and correlation of ITPA genotype-phenotype in a Caucasian population. Clin. Chem. 2006, 52:240-247.
133. Atanasova S., Shipkova M., Svinarov D., Mladenova A., Genova M., Wieland E., Oellerich M., von Ahsen N. Analysis of ITPA phenotype-genotype correlation in the Bulgarian population revealed a novel gene variant in exon 6. Ther. Drug Monit. 2007, 29:6-10.
134. L.L.C. Schrödinger, The PyMOL Molecular Graphics System, Version 1.4.1. 2011.
135. Ho B., Gruswitz F. HOLLOW. Generating accurate representations of channel and interior surfaces in molecular structures. BMC Struct. Biol. 2008, 8:49.
136. Kleywegt G.J., Jones T.A. Detection, delineation, measurement and display of cavities in macromolecular structures. Acta Crystallogr. D Biol. Crystallogr. 1994, 50:178-185.